This is the Continuous Integration Build of FHIR (will be incorrect/inconsistent at times).
See the Directory of published versions
Biomedical Research and Regulation Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: No defined compartments |
Raw Turtle (+ also see Turtle/RDF Format Specification)
Basic details of a product, only using MedicinalProductDefinition and no other resources
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- [a fhir:MedicinalProductDefinition ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "equilidem-basics"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n <p>\n <b>\n Generated Narrative\n </b>\n </p>\n <p>\n <b>\n Id\n </b>\n : equilidem-basics\n </p>\n <p>\n <b>\n Identifier\n </b>\n : Equilidem25\n </p>\n <p>\n <b>\n Combined Pharmaceutical Dose Form\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/dosefom tablet}\">\n tablet\n </span>\n </p>\n <p>\n <b>\n Indication\n </b>\n : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\n </p>\n <p>\n <b>\n Legal Status Of Supply\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/legalstatusofsupply POM}\">\n Prescription only medicine\n </span>\n </p>\n <p>\n <b>\n Classification\n </b>\n :\n <span title=\"Codes: {http://www.whocc.no/atc/example B01A}\">\n ATC: B01A\n </span>\n </p>\n <p>\n <b>\n Ingredient\n </b>\n :\n </p>\n <ul>\n <li>\n <span>\n Equilidonium Phosphate\n </span>\n </li>\n <li>\n <span>\n Calcium Carbonate\n </span>\n </li>\n </ul>\n <h3>\n Names\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Product Name\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n Equilidem 2.5 mg film-coated tablets\n </td>\n </tr>\n </table>\n <h3>\n Cross References\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Product\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n Link to generic equivalent\n </td>\n </tr>\n </table>\n <h3>\n Manufacturing/Business Operations\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Manufacturer\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n <span>\n EquiliDrugCo Inc.\n </span>\n </td>\n </tr>\n </table>\n </div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://example.org.uk/fhir/product"^^xsd:anyURI ] ; fhir:value [ fhir:v "Equilidem25" ] ] ) ; # fhir:combinedPharmaceuticalDoseForm [ fhir:coding ( [ fhir:system [ fhir:v "http://example.org.uk/fhir/dosefom"^^xsd:anyURI ] ; fhir:code [ fhir:v "tablet" ] ] ) ] ; # fhir:indication [ fhir:v "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."] ; # fhir:legalStatusOfSupply [ fhir:coding ( [ fhir:system [ fhir:v "http://example.org.uk/fhir/legalstatusofsupply"^^xsd:anyURI ] ; fhir:code [ fhir:v "POM" ] ; fhir:display [ fhir:v "Prescription only medicine" ] ] ) ] ; # fhir:classification ( [ fhir:coding ( [ fhir:system [ fhir:v "http://www.whocc.no/atc/example"^^xsd:anyURI ] ; fhir:code [ fhir:v "B01A" ] ] ) ] ) ; # fhir:ingredient ( [ fhir:text [ fhir:v "Equilidonium Phosphate" ] ] [ fhir:text [ fhir:v "Calcium Carbonate" ] ] ) ; # fhir:name ( [ fhir:productName [ fhir:v "Equilidem 2.5 mg film-coated tablets" ] ] ) ; # fhir:crossReference ( [ fhir:product [ fhir:reference [ fhir:reference [ fhir:v "MedicinalProductDefinition/genericEquilidonium" ] ] ] ] ) ; # fhir:operation ( [ fhir:organization ( [ fhir:display [ fhir:v "EquiliDrugCo Inc." ] ] ) # licence holder would use RegulatedAuthorization ] )] . # # -------------------------------------------------------------------------------------
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR ®© HL7.org 2011+. FHIR R6 hl7.fhir.core#6.0.0-ballot2 generated on Tue, Nov 19, 2024 06:10+0000.
Links: Search |
Version History |
Contents |
Glossary |
QA |
Compare to R5 |
|
Propose a change